Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AVEO Pharmaceuticals, Inc. |
---|---|
Information provided by: | AVEO Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00826878 |
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of AV-951 with this dosing schedule, as well as overall response rate of AV-951 administration in NSCLC.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung |
Drug: AV-951 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1b/2a Open-Label Study to Evaluate the Safety and Activity of Once Daily Oral Administration of AV-951 in Subjects With Non-Small Cell Lung Cancer |
Estimated Enrollment: | 53 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | November 2010 |
Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
AV-951: Experimental |
Drug: AV-951
Subjects will receive 1.0 or 1.5 mg AV-951 once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity. Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated. |
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of AV-951 with this dosing schedule, as well as overall response rate of AV-951 administration in NSCLC. There are no curative therapies for patients with advanced NSCLC, and therefore these patients represent an unmet medical need. Agents targeting the VEGF pathway, such as bevacizumab and Axitinib, have demonstrated clinical activity in NSCLC. Since AV-951 is a potent inhibitor of VEGFR tyrosine kinase, this study has been designed to test the clinical activity of AV-951 in NSCLC (in the phase 2a portion).
In the Phase 1b study, the dose of AV-951 administered will be escalated from 1.0 mg/day to 1.5 mg /day. Once the MTD of AV-951 and safety profile has been determined in the Phase 1b study, the Phase 2a study will be initiated to evaluate clinical activity. The Phase 2a study is a standard Simon 2-stage design. Twenty-one (21) subjects will be enrolled in Stage 1. If more than 1 confirmed response (CR + PR) is observed, the trial will proceed to Stage 2 and an additional 20 subjects will be enrolled. The MTD of AV-951 from the Phase 1b study will be used for all subjects treated in the Phase 2a study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, District of Columbia | |
Georgetown University | Recruiting |
Washington, District of Columbia, United States, 20007 | |
Contact: Patricia Dunn, RN 202-687-1569 | |
Principal Investigator: Jimmy Hwang, MD | |
United States, Kansas | |
Kansas University Medical Center | Not yet recruiting |
Kansas City, Kansas, United States, 66160 | |
Contact: Cinda Lyon 913-588-2567 clyon@kumc.edu | |
Principal Investigator: Karen Kelly, MD | |
United States, New York | |
Memorial Sloan-Kettering | Recruiting |
New York, New York, United States, 10021 | |
Contact: Valerie Baez 646-227-2183 baezv@mskcc.org | |
Principal Investigator: Naiyer Rizvi, MD |
Study Director: | Pankaj Bhargava, M.D. | AVEO Pharmaceuticals, Inc. |
Principal Investigator: | Jimmy Hwang, MD | Georgetown University |
Principal Investigator: | Karen Kelly, MD | University of Kansas |
Principal Investigator: | Naiyer Rizvi, MD | Memorial Sloan-Kettering Cancer Center |
Responsible Party: | AVEO Pharmaceuticals, Inc. ( Margaret M. Taleff, Senior Director, Regulatory Affairs ) |
Study ID Numbers: | AV-951-08-105 |
Study First Received: | January 21, 2009 |
Last Updated: | February 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00826878 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |